Objective: Several outbreaks of multidrug resistant tuberculosis (MDR-TB) (utbreaks of multidrug-resistant tuberculosis -J(MDR-TB) have recently occurred, in which healthcare workers and others have become infected with Mycobacterium tuberculosis after exposure to patients with MDR-TB.12 Virtually all of the cases in the outbreaks have had organisms resistant to both isoniazid (INH) and rifampin (RIF) and several to other drugs. This has raised issues about the management of such contacts, including which preventive therapy regimen(s) might be used.
Objective: Several consensus. This presumably develops a group opinion without the need to gather physically the panel and avoids the impact of any one individual's personality and reputation on the consensus-building process.
Because there are no clinical data to guide whether preventive therapy should be used for contacts infected with MDR-TB, or which drugs should be considered for such a regimen, we formed a panel of 31 experts in the field of TB therapy and conducted a Delphi survey.
METHODS
In our study, we modified the Delphi survey technique by presenting three clinical scenarios and predetermining that a total of only three survey rounds would be performed.
An initial panel of 31 experts in TB treatment was chosen from the membership of the American Thoracic Society (ATS) Scientific Assembly of Microbiology, Tuberculosis and Pulmonary Infections. To prevent any particular individual from influencing the decisions of others, the identity of the panel members and their individual preferences were not revealed.
Delphi Survey Cases
In the past few months several individuals have been evaluated for preventive therapy due to nosocomial exposure to tuberculosis. These people have probably been exposed via patients on a medical-surgical floor where there has been a concentration of tuberculosis patients. Unfortunately, approximately 50 percent of the patients on the ward had disease caused by isoniazid/ rifampin-resistant organisms with a significant but unknown percentage reported as being resistant to ethambutol as well. All of the exposed persons had previously documented negative tuberculin skin tests (Mantoux) less than 1 y prior and had spent a significant period on the floor in question. The exposed persons included: 1) a 40-y-old nurse with a 15 mm Mantoux tuberculin test; 2) a 32-y-old HIV+ patient with a 15mm Mantoux tuberculin skin test; 3) a 45-y-old anergic HIV+ patient who shared the room of a resistant case.
In the first survey round, each scenario was presented and possible preventive therapy regimens were solicited from the members of the panel. The panel member's initial responses were listed by the investigators as possible regimens for each scenario, any regimen suggested by at least one participant was included.
The lists of possible regimens for each scenario were returned to the panel members in a second survey round which required the members of the panel to rank each listed treatment option from one to nine with one being considered an extremely inappropriate, nine an extremely appropriate, and five an equivocal treatment. The frequency with which each level of appropriateness was chosen for each option was calculated and visually presented in the form of histograms during the third and final survey round. Each panel member's prior choice (from round 2) was indicated on his or her individual survey form as a reminder. The panel members were again asked to consider the group results, and re-evaluate their initial rankings during this final round of the survey. Of the original 31 panelists, 23 responded to round 2 and 20 to round 3. The round 2 responses of the panelists who failed to respond to the round 3 Delphi were incorporated into the final survey results.6
The delphi survey data were analyzed using the SAS computer statistical package.7 Summary statistics such as medians and interquartile ranges were generated and reviewed for each treatment within each clinical scenario. The median value is used to identify the location on the appropriateness scale and the interquartile range (ie, a measure of dispersion generated by taking the difference between the 75th and the 25th percentiles) of "2" or less is used as the predefined criteria for indicating consensus. Data were also analyzed in terms of what percentage of respondents felt a treatment option was at all appropriate (six or more on the scale).
RESULTS
The The approach to a patient with TB infection is a critical problem. The decision to prescribe preventive therapy is dependent on various positive and negative contributing factors. The most important positive factor for preventive therapy is the risk of the *IQ=interquartile; range=75% to 25% value. iPercent responding with a rank of 6 or more on the 9-point appropriate particular infected individual developing active TB. Another positive factor, is any potential public health risk represented by an active TB case. The third factor is the likelihood that the individual is infected with MDR-TB, which presents a broad new and confounding variable. Negative contributing factors would be drug related: ie, risk of the preventive regimen to the patient, potential risk of the treatment regimen if the individual subsequently develops active TB, and finally, cost of the drugs prescribed.
In our survey, we designed the cases to vary the weights of these variables. We attempted to increase the value of the first variable by presenting all of the patients as new skin test reactors, with the exception of the patient who is anergic HIV-positive, thus at high risk of developing active TB according to ATS-CDC criteria.3 The anergic patient's risk would also be considered increased, by virtue of his immunocompromised state and the extremely close contact of sharing a room with an MDR-TB case.2'4 The nurse would also represent a public health risk. If this individual was to develop active transmissible MDR-TB, there may be an increased risk of nosocomial spread, as previously described." 2 The likelihood of a skin test conversion being secondary to MDR-TB infection is essentially an unknown and probably unquantifiable. In the absence of hard data, however, we think, and so apparently did our panel, that the presence of MDR-TB infection must be strongly considered in these contacts.
In evaluating the likelihood that a new tuberculin conversion is due to an MDR-TB organism, one can 
